Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Hutchison MediPharma Says HMPL-004 Meets Trial Endpoints

publication date: Nov 6, 2009

Hutchison MediPharma reported its lead drug candidate, HMPL-004, met all endpoints in a Phase IIb clinical trial in patients with mild-to-moderate active Ulcerative Colitis. Last summer, the company announced that early data showed HMPL-004 was effective in another Phase II trial, this one conducted in patients with Crohn’s disease. HMPL-004 is a proprietary oral compound that is extracted from a China herb and retards inflammation through a novel mechanism. More details...

Stock Symbol: (AIM: CHM)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital